CRI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Carter's Inc (CRI) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some supportive signs, including recent price-target raises, a dividend declaration, and a few positive business-recovery comments from analysts, but the overall setup is still mixed. The technical trend is not clearly bullish, options sentiment is constructive but not strong enough to override the weak price structure, and Intellectia signals show no active buy setup today. My direct view: do not buy aggressively at current levels; hold and wait for a cleaner long-term entry.
Current price is 33.6, slightly below the previous close of 33.76, with the stock closing lower after a modest regular-session move and a small post-market dip. The MACD histogram is -0.325 and still below zero, which indicates bearish momentum, though the negative pressure is slowly contracting. RSI_6 at 42.1 is neutral and does not show oversold strength. Moving averages are converging, suggesting the stock is stabilizing but not yet in a confirmed uptrend. Key levels: support at 32.48 and 30.75, resistance at 38.06 and 39.78. Overall, the chart is range-bound to slightly weak, not a convincing entry for an impatient long-term buyer.
["UBS raised price target to $41 from $40 after a strong first quarter and improving business momentum.", "Goldman Sachs upgraded the stock to Neutral from Sell and raised the target to $38, citing a meaningful sales growth opportunity.", "Monness Crespi upgraded to Buy with a $45 target, arguing tariffs may be masking the turnaround.", "The company declared a quarterly dividend of $0.25 per share, reinforcing shareholder return support.", "Aristides Capital increased its stake by 90,533 shares in Q1 2026, suggesting some investor confidence in a recovery."]
["UBS still kept a Neutral rating, citing CEO-transition uncertainty, input cost pressures, and limited long-term growth potential.", "Wells Fargo remains Underweight and warned about risk into quarterly results and lack of full-year guidance upside.", "Needham took a wait-and-see stance due to macro uncertainty.", "Technical momentum remains weak with MACD below zero and no confirmed bullish trend.", "No AI Stock Picker or SwingMax buy signal is active today.", "Hedge fund and insider trading trends are neutral, with no significant accumulation signal.", "No recent congress trading data is available."]
Latest quarter financial snapshot was not provided due to data error, so I cannot verify the exact numbers. Based on analyst commentary, the company appeared to post a strong first quarter with improving business momentum, especially in direct-to-consumer comps, but there are still concerns around cost pressure and the sustainability of growth. Since the latest quarter season is not explicitly stated in the provided financial data, the only confirmed recent quarter reference is the first quarter discussed by analysts.
Analyst sentiment has improved modestly over the last few months. UBS raised its target to $41 and stayed Neutral, Wells Fargo raised its target to $33 but remained Underweight, Goldman Sachs upgraded to Neutral with a $38 target, Needham initiated Hold, and Monness Crespi upgraded to Buy with a $45 target. The Street view is mixed: the pros see recovery potential, better digital execution, and possible sales gains; the cons focus on CEO transition risk, input costs, macro uncertainty, and limited long-term growth. Net takeaway: analysts are less bearish than before, but the stock still does not have broad, strong-buy consensus.
